Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-05-03
2010-12-21
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S269000, C514S272000, C514S275000, C544S329000, C544S333000
Reexamination Certificate
active
07855212
ABSTRACT:
The present invention is related to pyridinyl acetonitriles as well as to pharmaceutical formulations containing such pyridinyl acetonitriles. Said pyridinyl acetonitriles are modulators of the protein kinase signalling pathways, particularly the one involving Glycogen Kinase Synthase 3 or JNK. The present invention is furthermore related to methods of preparing pyridinyl acetonitriles. X is a substituted or unsubstituted pyridinyl. G is an unsubstituted or substituted pyrimidinyl or triazinyl.
REFERENCES:
patent: 2676964 (1954-04-01), Papa et al.
patent: 461 079 (1991-12-01), None
patent: 752 424 (1997-01-01), None
patent: 1 110 957 (2001-06-01), None
patent: 02/20495 (2002-03-01), None
patent: 03/030909 (2003-04-01), None
Newkome, et. al., Organometallics (1988), 7(12), 2537-42.
http://www.nlm.nih.gov/cgi/mesh/2009/MB—cgi?mode=&index=18275&field=all&HM=&II=&PA=&form=&input, last accessed Jan. 3, 2009.
National Library of Medicine website, http://www.nlm.nih.gov/cgi/mesh/2009/MB—cgi, last accessed Jan. 3, 2009.
Zhi-Tang Huang et al., “Synthesis, reactions, and tautomerism of ketene N, S-acetals with benzothiazoline ring”, Chemische Berichte, vol. 123, No. 3, pp. 541-547 1990.
James R. Woodgett, “A common denominator linking glycogen metabolism, nuclear oncogenes and development”, Trends Biochem. Sci., vol. 16, pp. 177-181 1991.
Simon Lovestone, et al, “Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells”, Current Biology, vol. 4, No. 12, pp. 1077-1086 1994.
Janet Brownlees, et al., “Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3β transgenes”, Neuroreport, vol. 8, pp. 3251-3255 1997.
Akihiko Takashima et al, “Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 9637-9641 1998.
Zhuohua Zhang, et al., “Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis”, Nature, vol. 395, pp. 698-702 Oct. 15, 1998.
Akihiko Takashima et al, “Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 7789-7793 1993.
Jin-Jing Pei, et al, “Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease Brain”, Journal of Neuropathology and Experimental Neurology, vol. 56, No. 1, pp. 70-78 1997.
Guang Chen, et al., “The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3”, Journal of Neurochemistry, vol. 72, No. 3, pp. 1327-1330 1999.
Shigeyuki Nonaka, et al, “Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-d-aspartate receptor-mediated calcium influx”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 2642-2647 1998.
Robert Joseph Thomas, “Excitatory amino acids in health and disease”, J. Am. Geriatr. Soc., vol. 43, pp. 1279-1289 1995.
Chihoko Sasaki et al, “Different expression of glycogen synthase kinase-3β between young and old rat brains after transient middle cerebral artery occlusion”, Neurological Research, vol. 23, pp. 588-592 2001.
Darren A. E. Cross, et al, “Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death”, Journal of Neurochemistry, vol. 77, pp. 94-102 2001.
Adnan Ali et al, “Glycogen synthase kinase-3: properties, functions, and regulation”, Chemical Reviews 2000.
Gaillard Pascale
Gotteland Jean-Pierre
Page Patrick
Schwarz Matthias
Thomas Russell J.
Merck Serono SA
Murray Jeffrey H
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Wilson James O
LandOfFree
Pyridinyl acetonitriles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridinyl acetonitriles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridinyl acetonitriles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172883